CD8A and hepatocellular carcinoma: To summarize, the best predictive models for PFS in ICB-treated patients involved adding the LAG-3+ cell proportion to the CD8+ cell proportion for all patients (ΔLRχ2 = 9.87, P = 0.002; Figure 5, Supplementary Table 6), adding the CD38+CD68+ cell proportion to the LAG-3+CD8+ cell proportion for viral-related HCC (ΔLRχ2 = 2.08, P = 0.15; Figure 5, Supplementary Table 8), and the LAG-3+ cell proportion alone for non-viral HCC (HR = 0.16, P = 0.004; Supplementary Table 7).